United Therapeutics Corporation

• UTHR Stock Price 24h change: -0.68%. From 483.23 USD to 479.96 USD. (Performance reflects a slight pullback amidst broader market volatility).
• From a technical perspective, UTHR is in a "short-term consolidation phase within a long-term bullish trend." While the stock remains above its 50-day ($473.90) and 200-day ($365.85) moving averages, recent indicators like the 14-day RSI (approx. 34.7) and a negative MACD crossover suggest short-term bearish momentum as the market digests previous gains near 52-week highs.
• CEO Martine Rothblatt is scheduled to present at the J.P. Morgan Healthcare Conference on January 12, 2026, providing a high-profile platform to update investors on the company's PAH pipeline and growth strategy.
• Analysts maintain a "Strong Buy" consensus on UTHR with a median price target of $537, citing strong free cash flow ($734.6 million) and the clinical potential of Tyvaso DPI and Ralinepag.
• Mergers and acquisitions remain a core theme in the biotech sector as Merck reportedly entered talks to acquire Revolution Medicines (RVMD), which surged 15% following the news.
• The broader biotech industry has seen increased volatility in early January 2026, with investors favoring clinical-stage companies with significant "Total Addressable Markets" (TAM) over established giants facing patent cliffs.

• UTHR Stock Price 24h change: -1.55%. From 490.83 USD to 483.23 USD. The decline was likely influenced by broader sector caution and recent insider selling reports.• From a technical perspective, the stock is showing a "short-term bearish consolidation" within a long-term bullish trend. While the 14-day RSI of 34.77 and a negative MACD signal near-term selling pressure, the price remains above its 200-day moving average ($402.27), suggesting the primary upward trend is still intact despite the recent pullback from all-time highs.• United Therapeutics CEO Dr. Martine Rothblatt is scheduled to present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.• Recent SEC filings revealed notable insider activity, including COO Michael Benkowitz selling shares worth approximately $7.1 million on January 5, 2026.• The company continues to advance its "EXPAND" clinical trial, recently announcing the first transplant of a U-Kidney in a patient with end-stage renal disease.• The 2026 biotech IPO market opened with significant momentum as Aktis Oncology raised $318 million in an upsized offering, backed by a $100 million investment from Eli Lilly.• A J.P. Morgan report ahead of the annual healthcare conference highlighted a shift in venture capital toward "de-risked" assets, as investors exercise greater caution with early-stage biotech funding.